Company intelligence / Profile preview

Bond Biosciences

Kansas City, Missouri, United Statesbond.bio ↗

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

Bond Biosciences has completed a first-in-human Phase Ia/b trial of its lead candidate BBI‑001, demonstrating that the drug was well-tolerated with no drug-related adverse events and effectively reduced dietary iron absorption. These results support advancement to Phase II studies to evaluate whether BBI‑001 can reduce or eliminate the need for phlebotomy in adults with hereditary hemochromatosis.[4][6]

Therapeutic areas: OtherHematology
Modalities: Non-absorbed small molecules[7][8][9]
Industry: Biotech

Drug pipeline

1 asset

BBI-001

Partnerships

No major pharmaceutical or biotech partnerships disclosed as of May 2025.

Beyond the preview

Go deeper on Bond Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bond Biosciences.

Explore the full profile